What We're Reading: Page 253
Industry reads hand-picked by our editors
Oct 23, 2018
-
The Wall Street Journal
The Illegal Ingredients in Your Dietary Supplements - WSJ
-
BioCentury
FDA advisory committee to consider CV studies for diabetes drugs
-
STAT
Mallinckrodt will be honored for research into a drug that causes sticker shock
-
Reuters
Johnson & Johnson makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z
Oct 22, 2018
-
The Wall Street Journal
A Billionaire Pledges to Fight High Drug Prices, and the Industry Is Rattled
-
The New York TImes
What Big Pharma Fears Most: A Trump Alliance With Democrats to Cut Drug Prices
-
Reuters
Merck KGaA says might strike partnership deal this year
-
STAT
Saving Mila: How doctors raced to stop a young girl's rare disease
Oct 19, 2018
Oct 18, 2018
-
MIT Technology Review
We can now customize cancer treatments, tumor by tumor
-
Bloomberg
An ETF banking on the next big drug breakthrough
-
The Washington Post
Big Pharma is hurting drug innovation
-
Associated Press
Rising drug prices widen gap between have, have-not patients
Oct 17, 2018
Oct 16, 2018
-
FiercePharma
Got tech ideas for diabetes? Novo wants you for its crowdsourcing challenge
-
The Atlantic
Neanderthals suffered a lot of traumatic injuries. So how did they live so long?
-
The New York Times
Most white Americans' DNA can be identified through genealogy databases
-
Stat
Harvard and the Brigham call for more than 30 retractions of cardiac stem cell research
Oct 15, 2018
-
BBC
Why gene editing could create so many jobs
-
The New York Times
Tiny nanoparticles to treat a huge problem: Snakebites
-
The Wall Street Journal
Chinese drugmaker’s IPO tests a slumping biotech market
Previous
